Pharmacy
Hospitals and health systems share concern about chronic and increasing drug shortages that have serious consequences for patient safety, quality of care and access to therapies. Addressing drug shortages is complex and costly to hospitals and health systems in terms of staff time and other…
The state of California put up $50 million to have Civica Rx manufacture and distribute low-cost biosimilars for the three most used short- and long-acting insulins.
The market for biosimilar drugs to treat cancer, inflammatory diseases, diabetes and more will continue to expand, ideally resulting in lower prices as more pharmaceutical patents expire and competitors enter the market.
The Food and Drug Administration yesterday revised its recent guidance for outsourcing facilities compounding certain ibuprofen oral suspension products.
Hosted by the American Hospital Association in partnership with McKesson
Join your hospital and health system executive peers in a virtual discussion to explore the barriers you face to streamline operational and access challenges to improve affordability and patient care excellence. …
In 2023, provider organizations can expect significant evolutionary changes in how to optimize patient engagement, the ever-expanding role that retail clinics will play in care delivery and some upheaval in venture capital funding for health care startups.
The market for pharmacy benefit manager services is highly concentrated, with commercial insurers often sharing ownership in the PBM, according to the analysis.
The FTC will launch an inquiry into the prescription drug middleman industry.
Increases in consolidation and alignment between commercial health plans and pharmacy benefit managers have resulted in a series of business practices designed to steer patients to insurer-affiliated pharmacies and away from patients’ longstanding providers to the detriment of patient care.
The AHA urges the FTC to increase scrutiny on insurer-mandated white bagging policies, as well as the impact of PBM-negotiated rebates and other business practices on the 340B drug discount pricing program and overall drug prices and drug price increases.